Form 4: InMed COO Granted 18,000 Stock Options

InMed Pharmaceuticals Inc. Chief Operating Officer Michael Woudenberg was granted 18,000 employee stock options with an exercise price of $1.29.

Summary

• Michael Woudenberg, Chief Operating Officer of InMed Pharmaceuticals Inc. (INM), was granted 18,000 employee stock options.
• The options have an exercise price of $1.29 per share.
• The grant date for these options was December 19, 2025.
• These options will vest in equal monthly installments over a 36-month period (1/36 per month).
• The options are set to expire on December 18, 2030.
• Following this transaction, Mr. Woudenberg beneficially owns a total of 25,445 derivative securities.

Sentiment

Score: 6

Explanation: Slightly positive, as it represents a standard executive compensation practice that aligns management interests with shareholders, without indicating any immediate negative operational or financial news.

Positives

• The grant of stock options aligns the Chief Operating Officer's financial interests with those of shareholders, incentivizing long-term company performance.

Future Outlook

The granted options will vest monthly over the next 36 months, indicating a long-term incentive structure for the Chief Operating Officer tied to future company performance.

Industry Context

The granting of stock options is a common practice in the biotechnology and pharmaceutical industries to compensate executives, attract talent, and align management incentives with shareholder value creation, particularly in companies with long development cycles like InMed Pharmaceuticals.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages across the biotech and pharma sectors, comparable to practices at companies like Pfizer, Moderna, or smaller biotechs, though the specific number and exercise price are company-specific.

Stakeholder Impact

• Shareholders: The option grant aims to align the COO's interests with long-term shareholder value creation.
• Employees: Standard executive compensation practices can influence overall company morale and compensation structures.

Next Steps

• The options will begin vesting in equal monthly installments over the next 36 months, starting from the grant date of December 19, 2025.

Key Dates

Keywords

InMed Pharmaceuticals, INM, Stock Options, Executive Compensation, Insider Transaction, Form 4, Beneficial Ownership, Chief Operating Officer